BNTX vs. SOLV: A Head-to-Head Stock Comparison
Updated onHere’s a clear look at BNTX and SOLV, comparing key factors like historical performance, profitability, financial strength, growth, dividend, and valuation.
Company Profile
BNTX trades as an American Depositary Receipt (ADR), offering U.S. investors a convenient way to access its foreign-listed shares. In contrast, SOLV is a standard domestic listing.
| Symbol | BNTX | SOLV |
|---|---|---|
| Company Name | BioNTech SE | Solventum Corporation |
| Country | Germany | United States |
| GICS Sector | Health Care | Health Care |
| GICS Industry | Biotechnology | Health Care Equipment & Supplies |
| Market Capitalization | 24.64 billion USD | 13.20 billion USD |
| Exchange | NasdaqGS | NYSE |
| Listing Date | October 10, 2019 | March 26, 2024 |
| Security Type | ADR | Common Stock |
Historical Performance
This chart compares the performance of BNTX and SOLV by tracking the growth of an initial $10,000 investment in each. Use the tabs to select the desired time period. Data is adjusted for dividends and splits.
Historical Performance at a Glance
| Symbol | BNTX | SOLV |
|---|---|---|
| 5-Day Price Return | -1.88% | 5.39% |
| 13-Week Price Return | -9.19% | 5.94% |
| 26-Week Price Return | 9.09% | 2.91% |
| 52-Week Price Return | -7.53% | 8.02% |
| Month-to-Date Return | -0.79% | 9.59% |
| Year-to-Date Return | -9.53% | 14.53% |
| 10-Day Avg. Volume | 0.98M | 1.29M |
| 3-Month Avg. Volume | 0.84M | 1.03M |
| 3-Month Volatility | 40.02% | 26.54% |
| Beta | 1.42 | 0.92 |
Profitability
Return on Equity (TTM)
BNTX
-3.04%
Biotechnology Industry
- Max
- 96.19%
- Q3
- 12.45%
- Median
- -16.39%
- Q1
- -47.43%
- Min
- -131.19%
BNTX has a negative Return on Equity of -3.04%. This indicates the company is generating a loss for its shareholders, which can be a result of unprofitability or negative shareholder equity and is often a sign of financial distress.
SOLV
41.02%
Health Care Equipment & Supplies Industry
- Max
- 29.82%
- Q3
- 15.54%
- Median
- 9.69%
- Q1
- 5.19%
- Min
- -7.98%
SOLV’s Return on Equity of 41.02% is exceptionally high, placing it well beyond the typical range for the Health Care Equipment & Supplies industry. This demonstrates a superior ability to generate profit from shareholder investments, though it could also be inflated by high financial leverage.
Net Profit Margin (TTM)
BNTX
8.52%
Biotechnology Industry
- Max
- 84.13%
- Q3
- 19.34%
- Median
- -1.39%
- Q1
- -117.64%
- Min
- -296.77%
BNTX’s Net Profit Margin of 8.52% is aligned with the median group of its peers in the Biotechnology industry. This indicates its ability to convert revenue into profit is typical for the sector.
SOLV
18.13%
Health Care Equipment & Supplies Industry
- Max
- 24.65%
- Q3
- 14.10%
- Median
- 10.09%
- Q1
- 5.84%
- Min
- -6.13%
A Net Profit Margin of 18.13% places SOLV in the upper quartile for the Health Care Equipment & Supplies industry, signifying strong profitability and more effective cost management than most of its peers.
Operating Profit Margin (TTM)
BNTX
3.75%
Biotechnology Industry
- Max
- 78.85%
- Q3
- 20.86%
- Median
- 0.51%
- Q1
- -128.29%
- Min
- -315.84%
BNTX’s Operating Profit Margin of 3.75% is around the midpoint for the Biotechnology industry, indicating that its efficiency in managing core business operations is typical for the sector.
SOLV
25.11%
Health Care Equipment & Supplies Industry
- Max
- 31.34%
- Q3
- 18.36%
- Median
- 15.07%
- Q1
- 9.62%
- Min
- -0.13%
An Operating Profit Margin of 25.11% places SOLV in the upper quartile for the Health Care Equipment & Supplies industry. This signals a strong ability to translate revenue into operating profit, outperforming most of its competitors in core business efficiency.
Profitability at a Glance
| Symbol | BNTX | SOLV |
|---|---|---|
| Return on Equity (TTM) | -3.04% | 41.02% |
| Return on Assets (TTM) | -2.64% | 10.50% |
| Net Profit Margin (TTM) | 8.52% | 18.13% |
| Operating Profit Margin (TTM) | 3.75% | 25.11% |
| Gross Profit Margin (TTM) | 86.80% | 54.18% |
Financial Strength
Current Ratio (MRQ)
BNTX
7.12
Biotechnology Industry
- Max
- 15.83
- Q3
- 7.97
- Median
- 4.06
- Q1
- 2.64
- Min
- 0.72
BNTX’s Current Ratio of 7.12 aligns with the median group of the Biotechnology industry, indicating that its short-term liquidity is in line with its sector peers.
SOLV
1.50
Health Care Equipment & Supplies Industry
- Max
- 4.97
- Q3
- 2.92
- Median
- 2.12
- Q1
- 1.54
- Min
- 0.86
SOLV’s Current Ratio of 1.50 falls into the lower quartile for the Health Care Equipment & Supplies industry. This indicates a tighter liquidity situation and a more constrained capacity to handle short-term debt than many of its competitors.
Debt-to-Equity Ratio (MRQ)
BNTX
0.01
Biotechnology Industry
- Max
- 1.27
- Q3
- 0.62
- Median
- 0.13
- Q1
- 0.00
- Min
- 0.00
BNTX’s Debt-to-Equity Ratio of 0.01 is typical for the Biotechnology industry, indicating its use of leverage is in line with the sector norm. This suggests a balanced approach to its capital structure.
SOLV
1.03
Health Care Equipment & Supplies Industry
- Max
- 1.62
- Q3
- 0.74
- Median
- 0.47
- Q1
- 0.15
- Min
- 0.00
SOLV’s leverage is in the upper quartile of the Health Care Equipment & Supplies industry, with a Debt-to-Equity Ratio of 1.03. While this approach can boost equity growth, it also exposes the company to greater financial vulnerability.
Interest Coverage Ratio (TTM)
BNTX
-1.43
Biotechnology Industry
- Max
- 72.37
- Q3
- 1.71
- Median
- -15.18
- Q1
- -65.75
- Min
- -166.46
BNTX has a negative Interest Coverage Ratio of -1.43. This indicates that its earnings were insufficient to cover even its operational costs, let alone its interest payments, signaling significant financial distress.
SOLV
2.65
Health Care Equipment & Supplies Industry
- Max
- 56.35
- Q3
- 24.86
- Median
- 9.84
- Q1
- 3.86
- Min
- -21.65
In the lower quartile for the Health Care Equipment & Supplies industry, SOLV’s Interest Coverage Ratio of 2.65 indicates a tighter cushion for servicing debt, suggesting less financial flexibility than many of its competitors.
Financial Strength at a Glance
| Symbol | BNTX | SOLV |
|---|---|---|
| Current Ratio (MRQ) | 7.12 | 1.50 |
| Quick Ratio (MRQ) | 7.02 | 1.14 |
| Debt-to-Equity Ratio (MRQ) | 0.01 | 1.03 |
| Interest Coverage Ratio (TTM) | -1.43 | 2.65 |
Growth
Revenue Growth
EPS Growth
Dividend
Dividend Yield (TTM)
BNTX
0.00%
Biotechnology Industry
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
BNTX currently does not pay a dividend, resulting in a yield of 0%. This is a common strategy for growth-focused companies that prioritize reinvesting earnings, though it may be less typical in mature, income-oriented sectors.
SOLV
0.00%
Health Care Equipment & Supplies Industry
- Max
- 4.36%
- Q3
- 1.87%
- Median
- 0.82%
- Q1
- 0.00%
- Min
- 0.00%
SOLV currently does not pay a dividend, resulting in a yield of 0%. This is a common strategy for growth-focused companies that prioritize reinvesting earnings, though it may be less typical in mature, income-oriented sectors.
Dividend Payout Ratio (TTM)
BNTX
17.60%
Biotechnology Industry
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
At 17.60%, BNTX’s Dividend Payout Ratio is exceptionally high, exceeding the typical range for the Biotechnology industry. While this provides a significant return to shareholders, it may limit funds for reinvestment and could be difficult to sustain.
SOLV
0.00%
Health Care Equipment & Supplies Industry
- Max
- 160.00%
- Q3
- 67.77%
- Median
- 28.21%
- Q1
- 0.00%
- Min
- 0.00%
SOLV has a Dividend Payout Ratio of 0%, indicating it does not currently pay a dividend. This is a common strategy for growth-oriented companies that reinvest all profits back into the business.
Dividend at a Glance
| Symbol | BNTX | SOLV |
|---|---|---|
| Dividend Yield (TTM) | 0.00% | 0.00% |
| Dividend Payout Ratio (TTM) | 17.60% | 0.00% |
Valuation
Price-to-Earnings Ratio (TTM)
BNTX
--
Biotechnology Industry
- Max
- 115.91
- Q3
- 56.76
- Median
- 21.80
- Q1
- 15.79
- Min
- 4.51
P/E Ratio data for BNTX is currently unavailable.
SOLV
8.68
Health Care Equipment & Supplies Industry
- Max
- 67.59
- Q3
- 41.41
- Median
- 33.11
- Q1
- 22.82
- Min
- 8.68
In the lower quartile for the Health Care Equipment & Supplies industry, SOLV’s P/E Ratio of 8.68 suggests the stock may be undervalued compared to its peers, potentially presenting an attractive entry point for investors.
Price-to-Sales Ratio (TTM)
BNTX
7.89
Biotechnology Industry
- Max
- 58.56
- Q3
- 29.31
- Median
- 8.30
- Q1
- 4.89
- Min
- 0.86
BNTX’s P/S Ratio of 7.89 aligns with the market consensus for the Biotechnology industry. This suggests its valuation, based on sales, is seen as standard and is on par with its competitors.
SOLV
1.57
Health Care Equipment & Supplies Industry
- Max
- 9.49
- Q3
- 5.41
- Median
- 2.92
- Q1
- 1.97
- Min
- 0.61
In the lower quartile for the Health Care Equipment & Supplies industry, SOLV’s P/S Ratio of 1.57 indicates its revenue is valued more conservatively than most of its peers. This could present a compelling opportunity if the market has overlooked its sales-generating capabilities.
Price-to-Book Ratio (MRQ)
BNTX
1.11
Biotechnology Industry
- Max
- 17.92
- Q3
- 10.38
- Median
- 4.78
- Q1
- 2.85
- Min
- 0.78
BNTX’s P/B Ratio of 1.11 is in the lower quartile for the Biotechnology industry. From a value investing perspective, this is favorable, as it suggests the stock is trading at a discount to its net asset value and may offer a greater margin of safety.
SOLV
2.54
Health Care Equipment & Supplies Industry
- Max
- 10.77
- Q3
- 6.04
- Median
- 3.32
- Q1
- 2.31
- Min
- 0.83
SOLV’s P/B Ratio of 2.54 is within the conventional range for the Health Care Equipment & Supplies industry. This shows a balanced market view, where the stock’s price is neither at a significant premium nor a discount to the book value of its peers.
Valuation at a Glance
| Symbol | BNTX | SOLV |
|---|---|---|
| Price-to-Earnings Ratio (TTM) | -- | 8.68 |
| Price-to-Sales Ratio (TTM) | 7.89 | 1.57 |
| Price-to-Book Ratio (MRQ) | 1.11 | 2.54 |
| Price-to-Free Cash Flow Ratio (TTM) | 24.88 | 57.46 |